To include your compound in the COVID-19 Resource Center, submit it here.

UCB reports interim Phase II data for rozanolixizumab in thrombocytopenia

UCB S.A. (Euronext:UCB) reported interim data from 28 patients with primary persistent or chronic immune thrombocytopenia (ITP)

Read the full 177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE